GT Biopharma is trading 6.15% lower at $6.10, with no confirmed company-specific announcement explaining the decline. - A report published October 14 highlighted the October 9 registration of up to 13,502,835 shares for resale; the filing does not itself authorize immediate sales or establish a cause for today’s move. - The broader market is weaker: the S&P 500 is down 0.61% and Nasdaq Composite is down 0.84%. This may contribute to pressure, but the available evidence does not confirm a specific catalyst for the stock’s decline.